<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679132</url>
  </required_header>
  <id_info>
    <org_study_id>360039</org_study_id>
    <nct_id>NCT01679132</nct_id>
  </id_info>
  <brief_title>CVRx Barostim Hypertension Pivotal Trial</brief_title>
  <official_title>CVRx Barostim Hypertension Pivotal Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Barostimâ„¢ Hypertension Pivotal Trial is a prospective, randomized, controlled trial to
      demonstrate the safety and efficacy of the Barostim Neo system in subjects with resistant
      hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Safety Objective</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To demonstrate the safety of the Neo system by reporting all adverse events that are complications between implant and 30 days post-implant in the device arm.  The incidence of adverse events will be categorized by relatedness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Objective</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate a significant reduction between the two treatment arms of protocol defined automated office cuff systolic blood pressure (SBP) from baseline to 6 months post-activation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Objective 1</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate a significant reduction within the device arm of office cuff systolic blood pressure (SBP) between baseline and 12 months post-activation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Objective 2</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate a significant reduction within the device arm of 24-hour ambulatory systolic blood pressure (SBP) between baseline and 12 months post-activation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Objective</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To demonstrate the safety of the Neo system by reporting all hypertensive emergencies from activation to 6 months post activation.  The incidence of hypertensive emergencies will be categorized by study arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <arm_group>
    <arm_group_label>Neo Baroreflex Activation Therapy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive Neo Baroreflex Activation Therapy System device plus optimal medical management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Management Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are randomized to receive optimal medical management alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neo Baroreflex Activation Therapy System</intervention_name>
    <arm_group_label>Neo Baroreflex Activation Therapy System</arm_group_label>
    <other_name>Neo System</other_name>
    <other_name>Barostim Neo System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Highlights:

          -  Age at least 21 years and no more than 80 years at the time of randomization.

          -  On four or more maximally tolerated anti-hypertensive medications, one of which is a
             diuretic. The antihypertensive medication regimen must remain unchanged for 4 weeks
             prior to screening and must be expected to remain unchanged for at least 6 months
             during follow-up.

          -  Protocol defined systolic blood pressure greater than or equal to 160 mmHg.

          -  Protocol defined 24-hour Ambulatory Blood Pressure Monitoring (ABPM) greater than or
             equal to 135 mmHg.

          -  Serum estimated glomerular filtration rate (eGFR) &gt; 29 mL/min/1.73 m^2.

          -  Appropriate surgical candidate.

          -  Women of childbearing potential must use a medically accepted method of birth control
             and agree to continue use of this method for the duration of the study.  Women of
             childbearing potential must have a negative pregnancy test within 14 days prior to
             randomization.

        Exclusion Criteria Highlights:

          -  Known or suspected baroreflex failure or autonomic neuropathy.

          -  Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension,
             unstable angina, syncope, or cerebral vascular accident within the 3 months.

          -  Hypertension secondary to an identifiable and treatable cause other than sleep apnea.

          -  Prior surgery, radiation, or endovascular stent placement in the carotid sinus
             region.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Bakris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Chicago Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Bisognano, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Weaver, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Keck School of Medicine of the University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Abraham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Moore</last_name>
    <phone>763-416-2352</phone>
    <email>tmoore@cvrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Heart Rhythm Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Schwoegler</last_name>
      <phone>602-456-2342</phone>
      <email>wschwoegler@azheartrythm.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Swarup</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Romero</last_name>
      <phone>323-442-5322</phone>
      <email>romeroch@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Woo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Garey</last_name>
      <phone>202-741-3168</phone>
      <email>cgarey@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Trachiotis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cardiovascular Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Stastny</last_name>
      <phone>407-303-5600</phone>
      <phone_ext>1103439</phone_ext>
      <email>carol.stastny@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Harischandra Karunaratne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cardiovascular Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Lee</last_name>
      <phone>813-353-8535</phone>
      <email>courtneyelee@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Fadi Matar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Benoit</last_name>
      <phone>985-873-5613</phone>
      <email>deanna.benoit@cardio.com</email>
    </contact>
    <investigator>
      <last_name>Richard Abben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiac and Vascular Research Center of Northern Michigan</name>
      <address>
        <city>Petosky</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer LaLonde</last_name>
      <phone>231-487-9185</phone>
      <email>jlalonde@cvrcnm.com</email>
    </contact>
    <investigator>
      <last_name>Harry Colfer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan CardioVascular Institute</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tacey Gauthier</last_name>
      <phone>989-907-8031</phone>
      <email>tgauthier@mcvi.com</email>
    </contact>
    <investigator>
      <last_name>Naveed Akhtar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luzviminda Dizon</last_name>
      <phone>702-383-2585</phone>
      <email>luzviminda.dizon@umcsn.com</email>
    </contact>
    <investigator>
      <last_name>Chowdhury Ahsan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Miller</last_name>
      <phone>405-608-1280</phone>
      <email>bmiller@okheart.com</email>
    </contact>
    <investigator>
      <last_name>Branislov Schifferdecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Bernardini</last_name>
      <phone>412-359-5600</phone>
      <phone_ext>1103439</phone_ext>
      <email>sbernard@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Srinivas Murali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aspirus Wausau Hospital</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Kaliebe</last_name>
      <phone>715-847-2273</phone>
      <phone_ext>52639</phone_ext>
      <email>jeff.kaliebe@aspirus.org</email>
    </contact>
    <investigator>
      <last_name>German Larrain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 23, 2013</lastchanged_date>
  <firstreceived_date>August 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Resistant Hypertension</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
